{"schema_version":"secwatch.filing_event.v1","accession":"0001628280-23-015996","form_type":"8-K","ticker":"OVID","cik":"0001636651","company_name":"Ovid Therapeutics Inc.","filed_at":"2023-05-05T23:59:59+00:00","discovered_at":"2026-05-14T18:03:39.769776+00:00","generated_at":"2026-06-15T16:54:39.431176+00:00","sec_items":["2.02","9.01"],"event_type":"earnings","sentiment":"neutral","materiality_score":0.6,"calibrated_materiality_score":0.6,"confidence":"high","headline":"Ovid Q1 net loss $13.4M; cash $117.7M; adds ROCK2 program via Graviton","bullets":["Net loss $13.4M ($0.19 loss per share) vs $16.1M ($0.23) in Q1 2022; operating expenses $15.0M.","Cash, equivalents and marketable securities $117.7M as of March 31; expected runway into 2025.","Collaboration with Graviton adds GV101 (ROCK2 inhibitor); Phase 2 for brainstem cavernous malformations targeted for 2024.","OV329 Phase 1 on track with no safety signals; full data expected H1 2024; OV350 advancing preclinically.","Concluding Columbia University genetic collaboration by year-end; out-licensing options explored."],"urls":{"canonical":"https://secwatch.observer/filing/0001628280-23-015996","json":"https://secwatch.observer/filing/0001628280-23-015996.json","markdown":"https://secwatch.observer/filing/0001628280-23-015996.md","text":"https://secwatch.observer/filing/0001628280-23-015996.txt","edgar_index":"https://www.sec.gov/Archives/edgar/data/1636651/000162828023015996/0001628280-23-015996-index.htm","edgar_primary_document":"https://www.sec.gov/Archives/edgar/data/1636651/000162828023015996/ovid-20230505.htm"},"model":{"generated_by":"deepseek-v4-flash:cloud@v2","generated_at":"2026-06-15T16:54:39.431176+00:00"},"review":{"review_status":"machine_generated","human_reviewed":false,"corrected":false,"correction_note":null,"correction_timestamp":null,"superseded_by":null,"related_filings":[]},"source_grounded_claims":[{"claim_id":"78fa5ae4e8495aa3791023b4c430d3952564e2fa","claim":"Ovid Therapeutics Inc. reported financial results for the first quarter ended March 31, 2023.","evidence_excerpt":"On May 5, 2023, Ovid Therapeutics Inc. (the “Company”) issued a press release announcing First Quarter 2023 Financial Results and Corporate Updates.","evidence_source":"SEC 8-K Item 2.02","evidence_url":"https://www.sec.gov/Archives/edgar/data/1636651/000162828023015996/0001628280-23-015996-index.htm","confidence":0.4,"family_label":"Earnings Releases","details":[{"label":"Period","value":"the first quarter ended March 31, 2023"},{"label":"Result","value":"reported results"}],"fact_type":"earnings_release"}],"license":"Source filings: public domain (SEC EDGAR). Summaries (headline + bullets): CC-BY-4.0; attribute https://secwatch.observer"}